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Abstract Cannabis consumption is temporally associated
with the development of first episode psychosis (FEP).
Whether or not the chronic use of this substance induces
structural brain changes that may be responsible for the
cognitive and psychological disturbances in this disorder is
still matter of debate. To address this issue, we compared
the magnetic resonance imaging (MRI)-assessed grey
(GM) and white matter (WM) changes in young FEP
patients between users versus non-users of cannabis. This
prospective study included 50 consecutive FEP subjects: 33
users (22.7 ± 4.1 years, 4 women) and 17 non-users
(23.9 ± 4.2 years, 10 women). Users were further divided
into 15 heavy (23.3 ± 4.5 years, 2 women) and 18 light
users (22.2 ± 3.8 years, 2 women) according to their
lifetime cannabis use. Voxel-based-morphometry (VBM)
analysis of GM and tract-based-spatial-statistics (TBSS)
analysis of WM were performed. Age and gender were
used as non-explanatory co-regressors. There were no
supra-threshold differences between user and non-user
groups for both GM and WM parameters. This was also the
case when only heavy users were compared to non-users.
Multivariate models controlling for age and gender con-
firmed these findings. We found no evidence for cannabis
consumption related alterations in GM or WM in FEP
subjects. Due to the strict correction for multiple compar-
isons and sample size, we cannot formally exclude subtle
morphometric changes associated with cannabis con-
sumption. However, even if present, such potential altera-
tions would be of low magnitude.
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Abbreviations
BPRS Brief psychiatric rating scale
DTI Diffusion tensor imaging
FA Fractional anisotropy
FEP First episode psychosis





TAP Test of attentional performance
TBSS Tract-based-spatial-statistics
TFCE Threshold-free cluster enhancement
VBM Voxel-based-morphometry
WM White matter
WMS-R Wechsler memory scale: revised
Introduction
First episode psychosis (FEP) is a major health problem in
young adults with a reported incidence rate of at least 1.5 %
per year in urban areas (Amminger et al. 2006). Cannabis use
is very frequent in all stages of psychosis (Regier et al. 1990)
and represents one of its main risk factors (Semple et al.
2005; Henquet et al. 2005; Moore et al. 2007). Previous
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studies have demonstrated alterations in both grey matter
(GM) [review see e.g. (Honea et al. 2005; Glahn et al. 2008;
Fornito et al. 2009; Fusar-Poli et al. 2011)] and white matter
(WM) [review see e.g. (Kyriakopoulos and Frangou 2009)]
in at-risk individuals and patients with early stages of psy-
chosis. Given the frequency of moderate to heavy cannabis
use in these groups, it has been thought that the chronic use of
this substance partly contributes to these structural changes
by affecting both GM densities and WM microstructure.
Most previous studies focused on FEP or early psychosis in
line with the hypothesis of an early toxic effect of cannabis
on brain maturation. Cross-sectional comparisons revealed
decreased GM densities in cannabinoid receptor rich areas
(i.e. temporal fusiform gyrus, parahippocampal gyrus,
insular cortex, precuneus, paracingulate gyrus, dorsolateral
prefrontal cortex, cerebellum) of these patients (Szeszko
et al. 2007; Bangalore et al. 2008; Cohen et al. 2011; James
et al. 2011). Volume loss and cortical thinning were also
described upon follow-up in FEP patients with heavy can-
nabis consumption (Rais et al. 2008, 2010; Habets et al.
2011). However, negative data were reported both in original
articles (Schnell et al. 2012; Wobrock et al. 2009) and a
systematic review (Malchow et al. 2012). Diffusion tensor
imaging (DTI) data on WM are not less conflicting. Chronic
cannabis use in FEP patients was associated with altered WM
microstructure, increased WM directional coherence or no
significant changes (Peters et al. 2009; Dekker et al. 2010; Ho
et al. 2011; James et al. 2011). Several methodological
limitations render difficult the interpretation of these data.
First, most of the previous studies explored either GM or
WM changes in limited series of FEP patients. Second,
positive data may reflect the concomitant presence of cog-
nitive deficits that have not been excluded in most of these
contributions. In the current investigation, we combined
neuropsychological assessment of attention and memory
performances, GM volumetry with voxel-based-morphom-
etry (VBM) (Ashburner and Friston 2000) and WM micro-
structure with tract-based-spatial-statistics (TBSS) (Smith
et al. 2006) in 50 young FEP patients with heavy, light or no
cannabis consumption. The main aim of this work is to
provide a detailed analysis of the cannabis-related structural
changes in FEP patients after controlling for the confounding
effect of cognitive status.
Materials and methods
Subjects
Fifty patients with a FEP were recruited from a specialized
inpatient service for young adults. A FEP was considered
on the presence of any DSM-IV diagnosis of a psychotic
disorder (schizophrenia, schizophreniform disorder,
schizoaffective disorder, manic or depressive episode with
psychotic symptoms and delusional disorder) with a total
duration of illness less than 1 year. For each patient, the
diagnosis at time of MRI was established by combining
information gathered from several sources (clinical pre-
sentation, relatives, staff members, and previous medical
records when available). All diagnoses were confirmed by
at least two independent psychiatrists blind to their
respective assessment (LC, FC and/or MM). In order to
cover the wide spectrum of psychosis, three diagnostic
categories were considered (Table 1): I, schizophrenia; II,
Other psychotic diagnosis (including schizoaffective dis-
order, schizophreniform disorder and delusional disorder);
III, Mood disorder with psychotic symptoms (including
manic or depressive episode with psychotic symptoms). At
the time of MRI, all patients had been receiving atypical
antipsychotic treatment (aripiprazole, clozapine, olanza-
pine, quetiapine or risperidone) for at least 2 weeks. Life-
time cannabis and substance use at time of MRI was
determined using the cannabis experience questionnaire
that was administrated by the clinical psychologist of the
care team (MA) (Di Forti et al. 2009). Subjects were not
included if they presented with a history of substance use
other than cannabis, nicotine or alcohol (use defined as
more than four separate occasions). Heavy cannabis use
was defined as near daily or more cannabis consumption
for at least 1 year prior to clinical presentation. Patients
consuming at lower frequencies prior to presentation were
categorized as light cannabis users, whereas patients with
ten lifetime cannabis consumptions or less were considered
as non-users.
Subjects were grouped as 33 users (22.7 ± 4.1 years, 4
women) and 17 non-users (23.9 ± 4.2 years, 10 women) of
cannabis. Users were further divided into 15 heavy
(23.3 ± 4.5 years, 2 women) and 18 light users
(22.2 ± 3.8 years, 2 women). The mean age at onset of
cannabis consumption was at age 15.5 ± 1.9 (age range:
13–20 years). We further divided the users according to the
age at onset in early (age 15 or less at onset) and late (age
16 or above at onset) groups. For two cases this informa-
tion was not available.
All subjects underwent neuropsychological testing of
attention and working memory performances within
2 months of MRI testing (MB or SB, fully certified neu-
ropsychologists). Attentional functions were tested using
the French computerized version of the test of attentional
performance (TAP) (Zimmerman and Fimm 1994). Visu-
ospatial and auditory working memory was evaluated with
the French version of the WMS-R span tasks (Wechsler
1981). Additional assessments included the global assess-
ment of functioning score (GAF) (Dufton and Siddique
1992) and Edinburgh handedness inventory (Oldfield
1971).
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The normal distribution of the demographic and clinical
data was tested by D’Agostino and Pearson omnibus nor-
mality tests. Normally distributed variables (age, visuo-
spatial and auditory working memory, attentional
flexibility) were analyzed using ANOVA group tests and
post-hoc pair-wise Bonferroni’s multiple comparison tests.
Variables without normal distribution (gender, handedness,
attentional inhibition) were analyzed using Kruskal–Wallis
group statistics and post-hoc pair-wise Dunn’s multiple
comparison tests.
MR Imaging
MR imaging was performed with a 1.5 T clinical routine
whole body scanner (Achieva, Philips Medical Systems,
Best, The Netherlands). 3D T1 MPRAGE: coronal acquisi-
tion, 124 slices, matrix 256 9 256, voxel size 0.94 9
0.94 9 1.5 mm3, TE 6 ms, TR 35 ms, 1 average. DTI: 30
diffusion directions, b = 1,000 s/mm2 isotropically dis-
tributed on a sphere, 1 reference b = 0 s/mm2 image with no
diffusion-weighting, axial acquisition, 70 slices, matrix
112 9 112, voxel size 2.0 9 2.0 9 2.0 mm3, TE 71.2 ms,
TR 13469.4 ms, 1 average. Additional sequences (T2w,
FLAIR) were acquired and analyzed to exclude other brain
pathology.
GM VBM Analysis of T1 Data
The VBM analysis was analyzed using the FSL software
package (http://www.fmrib.ox.ac.uk/fsl/, Version 4.1).
Standard processing steps were used, as described in detail
before (Smith et al. 2006, 2007). The essential processing
steps included brain extraction using BET (brain extraction
tool, part of FSL), tissue-type segmentation using FAST4
(part of FSL), non-linear transformation into MNI (Mon-
treal Neurological Institute) reference space and creation of
a study-specific GM template, to which the native GM
images were then non-linearly re-registered. The modu-
lated segmented images were then smoothed with an iso-
tropic Gaussian kernel with a sigma of 2 mm. Finally,
voxel-wise general linear model (GLM) was applied using
permutation-based non-parametric testing (RANDOMISE,
part of FSL), correcting for multiple comparisons imple-
menting threshold-free cluster enhancement (TFCE)
(Smith and Nichols 2009). Because of the significant dif-
ference in gender between the two groups, all calculations
were performed twice, once without and once with age and
gender as non-explanatory co-regressors. Fully corrected
p values \0.05 are considered as significant. Additionally,
the analysis was repeated with respect to the GAF score
using and age and gender as non-explanatory co-regressors.
Table 1 Demographic and clinical characteristics
Variables Cannabis users Non-users Statistical analysis
High dose Low dose
N 15 18 17
Age (years) 23.3 ± 4.5 22.2 ± 3.8 23.9 ± 4.2 NS
Gender (f/m) 2/13 2/16 10/7 Group**
high vs non*
low vs non**
GAF score 28.9 ± 10.4 33.5 ± 11.7 31.6 ± 12.1 NS
Medication type (ap/ap?ad/ap?ms) 11/2/2 15/3/0 13/3/1 NS
Medication CPZ equivalent (mg) 426.5 ± 281.5 296.2 ± 202.9 283.3 ± 262.2 NS
Diagnosis (I/II/II, see below) 9/3/3 11/1/6 6/4/7 NS
Handedness (EHI) 18.5 ± 1.7 18.6 ± 1.6 14.8 ± 7.4 NS
Visuospatial working memory (score) 17.2 ± 2.6 14.3 ± 7.9 12.0 ± 7.7 NS
Auditory working memory (score) 11.7 ± 3.4 8.9 ± 6.2 9.1 ± 6.0 NS
Attentional inhibition response time (ms) 570.0 ± 124.4 560.3 ± 91.1 556.0 ± 59.5 NS
Attentional flexibility response time (ms) 1166.0 ± 532.2 890.1 ± 202.8 1058 ± 273.1 NS
Essential demographic and clinical characteristics of the three study groups FEP subjects with high dose cannabis consumption, low dose
cannabis consumption and without concomitant cannabis consumption. Diagnoses are grouped into three categories according to DSM-IV
criteria: I, schizophrenia; II, other psychotic diagnosis (including schizoaffective disorder, schizophreniform disorder and delusional disorder);
III, mood disorder with psychotic symptoms (including manic or depressive episode with psychotic symptoms)
GAF global assessment of functioning, Ap 2nd generation antipsychotic, Ad antidepressant, Ms mood stabilizer, EHI edinburgh handedness
inventory
NS non significant (p [ 0.05); * p \ 0.05; ** p \ 0.01
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WM TBSS Analysis of DTI Data
The TBSS analysis of the DTI data was again done
implementing the FSL software package (http://www.
fmrib.ox.ac.uk/fsl/, Version 4.1), according to the stan-
dard procedure described in details (Smith et al. 2004). In
principle, TBSS projects all subjects’ FA data onto a mean
FA tract skeleton using non-linear registration. The tract
skeleton is the basis for voxel-wise cross-subject statistics
and reduces potential misregistrations as the source for
false-positive or negative results. The other DTI derived
parameters longitudinal (LD, also known as axial diffu-
sivity AD), radial (RD) and mean (MD) diffusivity were
analyzed in the same way re-using the spatial transforma-
tion parameters that were estimated in the initial FA
analysis. Similar to the VBM analysis discussed above,
voxel-wise statistical analysis was performed with TFCE
(Smith and Nichols 2009) correction for multiple com-
parisons, considering fully corrected p values \0.05 as
significant. As for the VBM analysis, all calculations were
performed twice with and without age and gender as non-
explanatory co-regressors due to the difference in gender
between groups. Equivalent to the VBM analysis, an
additional analysis was performed with respect to the GAF
score using and age and gender as non-explanatory co-
regressors.
Results
Demographic and clinical data are summarized in Table 1.
There was a clear predominance of women among non-
users (12 % of users and 59 % of non-users, p \ 0.05).
Symptomatology at initial presentation as measured by
GAF (DSM-IV) scores was consistent with clinically sig-
nificant acute psychosis (overall average score 31.5, range
15–55). There were no significant differences in age,
clinical symptom severity at initial presentation, diagnosis,
medication type and dose (chlorpromazine equivalents),
handedness, attention and memory performance between
the two groups. The average neurocognitive performance
of all groups falls within the normal age-adjusted range
(i.e. within one standard deviation of age-adjusted normal
means).
No supra-threshold differences at p \ 0.05 TFCE cor-
rected for multiple comparisons (VBM; TBSS FA, LD,
RD, MD) were found for the comparison of all users versus
non-users (see Fig. 1). In the same line, we separately
compared the groups of heavy users versus light users,
heavy users versus non-users and light users versus non-
users again yielding no supra-threshold difference (VBM;
TBSS FA, LD, RD, MD). The comparison between early
onset versus late onset, early onset versus controls and late
onset versus controls also showed no supra-threshold dif-
ferences for all MRI variables (VBM; TBSS FA, LD, RD,
MD). The inclusion of age and gender as non-explanatory
co-regressors led to similar results. The analysis with
respect to the GAF score also resulted in no supra-thresh-
old results.
Discussion
The present study did not identify changes in GM volume
and WM microstructure in FEP subjects with versus
without concomitant cannabis consumption. These nega-
tive data concerned not only light users but also young
patients with long-standing heavy consumption and do not
support the idea of cannabis-mediated neurotoxicity during
brain maturation in FEP.
The impact of cannabis consumption on brain structure
remains a highly controversial issue. Some lines of evi-
dence indicated that cannabis use in itself and in the
absence of psychosis can be deleterious for brain structure.
However, recent reviews on this subject have concluded
that overall, cannabis use has minimal or no effect on brain
structure in the general population (Martin-Santos et al.
2010; Quickfall and Crockford 2006). In respect to
Fig. 1 Illustrates the group
average grey matter (greyscale)
and white matter FA skeleton
(red–yellow) in MNI standard
space centered at MNI X = 0,
Y = 0, Z = 0. There were no
supra-threshold differences
between cannabis users and
non-users, nor between heavy
users versus light users, nor
between early onset versus late
onset
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cannabis use in psychosis, previous VBM studies in at risk
individuals, FEP and early stages of schizophrenia led to
discrepant data [for recent reviews see (Rapp et al. 2012)
(Hermann and Schneider 2012)]. The review by Rapp et al.
(2012) includes eleven studies identifying a decrease in
global or specific brain structures associated with cannabis
consumption in psychosis patients or at risk subjects. These
morphometric effects were particularly strong in brain
regions rich on cannabinoid receptors, including the cin-
gulum, the dorsolateral prefrontal cortex and the cerebel-
lum. The authors further conclude that psychosis patients
and at risk subjects might be particularly vulnerable as
similar brain volume loss is not consistently reported in
nonpsychotic and healthy samples. This vulnerability is
further supported by the recent review of Hermann and
Schneider (2012) concluding that brain alterations were
especially pronounced in schizophrenic patients with can-
nabis consumption. Furthermore, close relatives of
schizophrenic patients showed greater cannabis-associated
brain tissue loss. Nevertheless, this review also points out
that different components of cannabis might have differ-
ential effects, notably pointing to a potentially protective
effect of cannabidiol. Intriguingly, Schnell et al. found
increased GM in middle frontal gray matter in FEP patients
(Schnell et al. 2012). An increase of striatal GM density
was also reported by Potvin and coworkers in cannabis
users with psychotic symptoms (not only FEP) and con-
comitant alcohol abuse (Potvin et al. 2007). In the only
study that combined assessment of GM densities and WM
microstructure in adolescent-onset schizophrenia with
cannabis use, James et al. (2011) reported GM density loss
in the temporal fusiform gyrus, the parahippocampal gyrus,
the ventral striatum, the right middle temporal gyrus, the
insular cortex, the precuneus, the right paracingulate gyrus,
the dorsolateral prefrontal cortex, the left postcentral gyrus,
the lateral occipital cortex and the cerebellum.
DTI data in the field of cannabis use in psychosis were
not less discrepant. Supporting the idea of hyperconnec-
tivity in FEP, one recent study assessed young men with
FEP with or without cannabis consumption (Peters et al.
2009) and revealed increased directional coherence in the
bilateral uncinate fasciculus, the anterior internal capsule
and frontal WM in cannabis users. In the same line, Dekker
and collaborators reported increased vulnerability of cor-
pus callosum fibers in cannabis naı¨ve patients (Dekker
et al. 2010). In contrast to these results, decreased FA in
several brain regions including the brain stem, the internal
capsule, the corona radiata, and the superior and inferior
longitudinal fasciculus in cannabis users was reported in
adolescent-onset schizophrenia and FEP patients with early
cannabis use (Ho et al. 2011). Several methodological
differences may explain these striking discrepancies.
Firstly, most of the studies included a limited number of
cases and attempted three groups (controls, psychosis with
and without cannabis use) comparisons that limit their
statistical power. Secondly, age differences as well as
clinical parameters may further explain these discrepan-
cies. For instance, our FEP patients were older than those
of James et al. (average of 16 years) (James et al. 2011).
Diagnostic considerations may also be relevant in this
context. The majority of previous studies limited recruit-
ment to subjects diagnosed with schizophrenia. However,
in line with epidemiological evidence that cannabis con-
sumption is a risk factor for broadly defined psychosis
(James et al. 2011), our results include several forms of
psychosis. One other study (Wobrock et al. 2009) assessed
brain morphology for cannabis users and non-users
amongst subjects with more broadly defined psychosis
(schizophrenia and schizoaffective disorder) and also found
no significant structural differences. It is thus possible that
decreased GM densities and altered WM microstructure
may characterize a subgroup of very young FEP patients
with increased vulnerability to cannabis consumption. One
additional parameter to take into account here is the dose
and duration of cannabis consumption that is highly vari-
able among the previously cited studies. In the present
series, both dose and duration of cannabis consumption
were not related to MRI parameters. Moreover, all of our
cases were cognitively preserved at least for attention and
working memory. It is thus likely that our FEP cannabis
users had a less aggressive form of their disease not
associated with cognitive deficits in early life.
Strengths and Limitations
Since the main issue to address concerns the deleterious
effects of cannabis in FEP, this investigation includes only
clinically overt cases without comparisons with an ad hoc
control group. The present study has two main strengths.
Firstly, it combines GM densities and WM microstructure
investigation using a strict correction for multiple com-
parisons. Secondly, cannabis users and non-users did not
differ in terms of cognitive performances precluding the
presence of MRI differences that could be attributed to this
confounding factor. However, several limitations should
also be considered. The major limitation of the current
investigation is the relatively small sample size of 50 FEP
subjects. One should, however, consider that this sample
size of prospectively assessed FEP subjects with high MRI
data quality without for example motion artifacts is com-
parable to that of previous studies in this field. Despite the
comparable medication load at inclusion, we cannot for-
mally exclude that the chronic administration of these
agents may alter the quality of our observations. In fact,
previous studies showed that both typical and atypical
antipsychotics often display contradictory impacts on both
Brain Topogr (2013) 26:641–647 645
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GM and WM volumes (Ho et al. 2011; Smieskova et al.
2009; Navari and Dazzan 2009). However, this is an
unlikely scenario given the young age of the present
cohort.
The inverse conclusion, notably the absence of canna-
bis-related alterations in FEP subjects, is not warranted by
the current investigation for two main reasons. Firstly, the
TFCE multiple comparison correction compensates for
false positive but not false negative results since the sample
size of 50 consecutive subjects might have insufficient
statistical power to detect subtle yet significant group dif-
ferences in MRI parameters. However, even if present, it is
highly unlikely that such subtle cannabis-related alterations
in GM and WM would have a major effect on the long-
term evolution of FEP. Future longitudinal studies on
young and adult FEP patients combining structural and
functional MRI imaging, neuropsychological evaluation
including activation paradigms and quantitative assessment
of cannabis use are needed to explore the effect of the long-
term consumption of this drug on brain structure and
reactivity across the age spectrum of this disorder.
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